Sequenom Hammered by Market, Analysts | GenomeWeb

NEW YORK (GenomeWeb News) – The day after Sequenom's board of directors fired the firm's CEO and its senior VP of R&D, its shares tumbled 39 percent, and analysts who cover the firm noted a lack of clarity surrounding the investigation that led to the firing of those employees and surrounding the firm's technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.